Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indoxacarb is a synthetic oxadiazine insecticide developed by DuPont to control a variety of insect pests, particularly lepidopteran larvae. It is a non-systemic insecticide with both contact and ingestion activity. After absorption or ingestion, indoxacarb blocks voltage-gated sodium channels in insect neurons, preventing sodium ion influx, which disrupts nerve function, leading to paralysis and death. The insecticidal effect is mainly due to the S-enantiomer of indoxacarb. It is considered a "reduced risk" pesticide by the U.S. EPA, with moderate to low mammalian toxicity and no evidence of carcinogenic, mutagenic, or developmental effects when used as directed[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indoxacarb.